Instructions and Forms for Completing the Application
WHERE TO SEND THE APPLICATION
Applications should be submitted by the deadline stated in the RFA to email@example.com. File size limit is 20 MB. Once the application has been submitted, please send a second email to firstname.lastname@example.org without any attachments to notify HEI that your application has been submitted. ** Scroll down for preliminary and full application forms. **
Frequently asked questions
Applicants should submit a brief Preliminary Application that provides the following information: title, scientific rationale, a brief description of the study aims, design and methods, statistical methods, and anticipated results. An estimated total budget and study duration should be provided (no budget details are needed at this stage). In addition, brief biosketches (maximum 2 pages per person) of the principal investigator and key co-investigator(s) should be provided. Rosenblith Award applicants should include only their own biosketch. Co-investigators are not allowed under this RFA, only junior personnel are allowed. Mentors should be listed on the form; mentor biosketches are not needed at this stage. Cover letters and letters of recommendatiosn are also NOT needed at this stage.
Investigators should use the Preliminary Application Form provided for the RFA to submit the preliminary application. The preliminary application must be no longer than specified (using 11-point font size and 1-inch margins, single-spaced; including the cover page, but excluding references and biosketches); longer applications will be rejected. For the CVs, applicants can use HEI form F-9 or another format, as long as each biosketch is no longer than 2 pages. The application forms should be turned into a combined PDF with appropriate bookmarks before submitting.
Full applications must be submitted on the HEI Application for Research Agreement (forms F-1 to F-12). Applications should be typed single-spaced, within the margin limitations indicated on the forms (1 inch minimum), and using a minimum font size of 11 pt. Interactive forms can be downloaded by following the links at the bottom of this page. The combined forms should be turned into a PDF with appropriate bookmarks before submission.
Any contract awarded under this Request for Applications is expected to be funded in part by a grant from the U.S. Environmental Protection Agency. This award process will be subject to regulations contained in 40 CFR Subchapter B, and particularly Part 30 thereof. Neither the United States nor the U.S. Environmental Protection Agency is nor will be a party to this Request for Applications or to any resulting agreement.
HEI and its funded institutions are subject to the Office of Management and Budget and EPA accounting regulations. Please provide a DUNS number for your institution.
BUDGET (FORMS F-4 AND F-5)
Cost or Pricing Data: Provide adequate data and analysis to assure HEI that the proposed costs are necessary and reasonable and that adequate accounting procedures will be used.
For RFA 19-2, Walter A. Rosenblith New Investigator Award, the budget cap is $500,000 total (including indirect costs) for 3 years, with a suggested Year 1 budget of $150,000 and Years 2 and 3 at $175,000 per year. For applications responding to RFA 19-2, the budget should be prepared assuming a project start date of February 1, 2021.
For RFA 20-1A, Health Effects of Air Pollution, the budget cap is $500,000 (total including indirect costs) for a 2-year study and $800,000 for a 3-year study. For applications responding to RFA 20-1A, the budget should be prepared assuming a project start date of February 1, 2021.
For RFA 20-1B, Air Pollution, COVID-19, and Human Health, the budget cap is $250,000 (total including indirect costs) for a 1-year study and $500,000 for a 2-year study. For applications responding to RFA 20-1B, the budget should be prepared assuming a project start date of February 1, 2021.
The total budget should include funds and an appropriate percent effort from key personnel for writing the final report in the final year of the study. Investigators should also be aware that additional time effort is expected at a later time to address requests for revisions and answering editorial queries. Please refer to the Final Report section in HEI Project Negotiation, Management, and Investigator Commitments (see separate document) for details.
List the names and positions of all applicant organization personnel involved in the project, both professional and nonprofessional, whether or not salaries are requested. Estimate the percentage of time or effort, or hours per week, on the project for professional personnel in relation to the total professional activity commitment to the applicant organization; estimate the hours per week on the project for nonprofessional personnel. List the dollar amounts separately for each individual for salary and fringe benefits. Fringe benefits may be requested to the extent that they are treated consistently by the applying organization as a direct cost to all sponsoring agencies.
The amount to be reimbursed to each individual, when added to his or her compensation for all other full-time duties, should not exceed the individual’s base salary. In computing estimated salary changes, an individual’s base salary represents the total authorized annual compensation that an applicant organization would be prepared to pay for a specific work period whether an individual’s time is spent on sponsored research, teaching, or other activities. The base salary for the purposes of computing charges to an HEI Research Agreement excludes income that an individual may be permitted to earn outside of full-time duties to the applicant organization.
Where appropriate, indicate whether the amounts requested for the principal investigator and other professional personnel are for summer salaries or academic-year salaries and indicate the formulas for calculating summer salaries.
Indicate whether current rates or escalated rates are used. If escalation is included, state the degree (percent) and methodology, e.g., annual flat rate applied to base rate as of a specific date or a mid-point rate for the period of performance.
Note that under the Walter A. Rosenblith New Investigator Award, senior personnel and mentors cannot be included for salary support. Consultants (e.g. for biostatistical support) are allowed.
HEI requires the involvement of a (bio)statistician in the study design, selecting appropriate statistical approaches, and the final data analysis and interpretation. Statisticians can be included under the main study personnel or as consultants. If the investigator’s Institution provides core statistical services, this should be indicated; in this case, a particular statistician should be identified by name. Exemption from this requirement can be obtained only if the Principal Investigators or other key personnel have appropriate expertise in this area, evidence of which should be submitted as part of the application. The statistician’s involvement should be evident in the application, for example by including a letter from the statistician indicating that they have read the application and approve the study design and statistical approaches. (See also Additional Submissions below).
Consultant service should be explained by indicating the specific area in which such service is to be used. Identify the contemplated consultants. State the number of days of such services estimated to be required and the consultant’s quoted rate per day, and indicate the number of hours per day in which work will be performed. The maximum consultant rate is $655.38/8-hr day. HEI’s participation in consultant costs is subject to limits set by federal regulations. (See also Additional Submissions below).
SUPPLIES AND OTHER EXPENSES
All supplies and other expenses should be itemized in sufficient detail to allow reviewers to understand the major categories of expenditures (i.e., glassware, media, chemicals, animal purchase and housing, as well as publication costs, page charges, and books, listed by category and unit cost). Itemize and justify such items as patient compensation, travel, and per diem costs, rentals, leases, and computer costs. Unusually expensive items for special processes should be separately identified by quantity and price and the use or application thoroughly explained in the project plan. Each individual expense item must be categorized as supplies or other expenses according to the practices of the accounting office of your institution. Items that cost more than $5,000 should be listed under equipment (see below).
The costs of construction per se are not permissible charges. If the costs of essential alterations of facilities, including repairs, painting, removal or installation of partitions, shielding, or air conditioning, are requested, itemize them by category and justify them fully. When applicable, indicate the square footage involved, giving the basis for the costs, such as an architect’s or applicant’s detailed estimate. When possible, submit a line drawing of the alterations being proposed.
Limit travel to one scientific meeting per year. Do not include the travel to the HEI Annual Conference within the budget, since HEI will cover these costs directly. If travel is required for other purposes, such as meetings with collaborators, indicate the estimated number of trips, destination, reason for travel, and cost. Identify and support any other special transportation costs attributable to the performance of this project. HEI pays for foreign travel only if it is approved in advance of the trip.
Indirect costs are limited to a maximum of 30% of direct costs excluding equipment charges and subcontracts. Indirect costs cannot be greater than the government-negotiated rate for your institution. Expenses normally included in the calculation of the indirect cost rate may not be itemized as direct expenses. A copy of your institution’s most recent approved indirect cost rate should be sent to HEI once the study has been approved for funding (it is not needed with the application).
The HEI Board of Directors has approved a very limited exception to this cap on indirect costs for organizations that can meet both of the following conditions: (1) the research institution provides a unique capability for a project essential to HEI’s mission, and (2) the institution is prohibited by the U.S. Government from accepting less than full cost recovery.
Provide an itemization and justification of all equipment to be purchased or fabricated for use in this study. Please note that HEI reimburses institutions only for those equipment items explicitly listed in the Approved Budget or subsequently authorized in writing by HEI’s Director of Science or Director of Finance & Administration. The equipment budget is not subject to indirect cost charges. Equipment valued less than $5,000 should be listed under supplies.
Itemize and enter a total for these costs. Describe and justify all appropriate costs for services purchased for, or associated with, third parties, including applicable indirect costs. These costs may include, but are not necessarily limited to, consortium agreements or formalized collaborative agreements. Indirect costs for subcontracts are also subject to HEI’s 30% cap (see above). Develop separate budgets for the initial and future budget periods for each organization involved in consortium arrangements or formalized collaborative agreements, and submit them using the appropriate budget form (F-4b and F-5b). The principal investigator’s institution may charge Indirect costs to the first $25,000 of each subcontract.
PROJECT PLAN (FORM F-6)
The Project Plan should include all the sections listed below. Include sufficient information in the Project Plan and in any appendix to facilitate an effective review. Be specific and informative and avoid redundancies. Sections A, B, and C together should total no more than four single-spaced pages. The Institute reserves the right not to consider proposals that exceed this limit. Appendices may be provided as supplementary information, but review will be based mainly on the information provided in the Project Plan. Section D should be concise but adequately detailed to permit critical evaluation. Sections D and E combined should not exceed 15 pages (excluding references). Please use an 11-point font size or larger and 1-inch margins.
State concisely and realistically what the research described in this application is intended to accomplish and/or what hypothesis is to be tested.
B. Anticipated Results and Significance
Briefly sketch the background to the present proposal, critically evaluate existing knowledge, and specifically identify the gaps that the project is intended to fill. State concisely the importance of the research described in this application by relating the specific aims to the stated objectives of HEI and explain the regulatory significance.
C. Related Previous Studies
Provide an account of, and references to, the principal investigator’s previous studies pertinent to the application and/or any other information, including preliminary findings, that will help to establish the experience and competency of the investigator to pursue the proposed project. The appendix can be used for published references or details of available pilot studies.
D. Experimental Plan and Methods
Discuss in detail the experimental design and the procedures to be used to accomplish the specific aims of the project.
Define your study sample (such as cell type, animal strain, or subject population) and explain the rationale for choosing it. If the study involves human participants, describe how they will be selected, and the informed consent procedure. (See Additional Submissions below).
HEI is committed to research that can lead to a better understanding of health responses of all members of the general population, particularly the most sensitive. Accordingly, consider the composition of the study population, including gender, racial/ethnic composition, and other aspects that might affect response, and provide a rationale for the choice of composition.
Provide sufficient details of the experimental design and study protocol so that it can be understood clearly by the reviewers. Applicants should provide details of exposure systems for specific pollutants (and the rationale for their selection), randomization procedures, methods used for any blinding of observations, and the proposed number of observations (including number of animals or participants and exposure groups), preferably with a power calculation. Describe any new methodology and its advantage over existing methodologies. For in vitro and in vivo exposure studies, methods to generate, monitor, and analyze exposure concentrations and composition should be described in detail. HEI is not enthusiastic about funding studies with older engines and fuels or SRM samples; however, they could serve as positive controls for the proposed experimental treatment.
Discuss the potential difficulties and limitations of the proposed procedures and alternative approaches to achieve the aims.
Where appropriate, describe the procedures to be used to ensure that the quality of the data is adequate in view of the objectives of the study (see Quality Assurance and Quality Control in HEI Project Negotiations, Management, and Investigator Commitments [separate document]). However, detailed QA information should not be submitted with the original application but will be requested for successfully funded studies that meet the above criteria.
E. Statistical Design, Analysis Plans, and Access to Data
Provide calculation of statistical power, and a justification of the proposed numbers of animals/participants/samples. Include a description of the statistical methods to be used for analysis and interpretation of the data. Describe the proposed statistical procedures with sufficient detail to allow evaluation by a biostatistical reviewer. HEI requires that a statistician is part of the study team, either listed under study personnel or as a consultant. It should be evident that s/he has reviewed the study design and data analysis plan. HEI recommends including power calculations where possible. Please note that in addition to reviews by experts in the subject matter, HEI often asks statisticians to review the statistical design of studies.
Investigators should include a plan for data sharing and data accessibility at the end of the study. lease see HEI’s Policy on Data Access.
F. Milestones and Timeline
Please include a list of milestones to be met during the project, with a timeline. Please use this template and fill in the cells to indicate when a specific aim or task will be ongoing and completed.
|Specific Aim 1: (add text)
|Task 1: (add text)
|Task 2: (add text)
G. Literature Cited
References in the text should consist of author and year. Provide complete citations in alphabetical order at the end of the Project Plan.
OTHER SUPPORT (FORM F-7)
Describe current and pending grants or contracts — whether from public or private sources — from which the investigators included in the proposed project are now drawing or anticipate drawing support, including any in-kind contributions. Identify program by title, agency, or organization supporting such work, and level of financial support given, and the percentage of time spent on each project. Briefly describe the contents of each. If any of these overlap, duplicate, or are being replaced or supplemented by the present application, justify and delineate the nature and extent of the scientific and budgetary overlaps or boundaries.
RESOURCES AND ENVIRONMENT (FORM F-8)
Describe all the facilities to be used and, in the space provided, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project. List the most important equipment items available for this project, noting the location, and pertinent capabilities of each.
BIOGRAPHICAL SKETCHES (FORM F-9)
Provide information on the education and research and/or professional experience for professional personnel and consultants beginning with the Principal Investigator. Do not exceed 2 pages per individual.
ADDITIONAL SUBMISSIONS (FORM F-10)
If Item 6 on the Title Page (Form F-1) of the application has been marked “YES,” submit OMB form No. 0990-0263 (Form F-11 of HEI application forms).
Safeguarding the rights and welfare of human participants in projects supported by EPA grants is the responsibility of the institution, which receives or is accountable to EPA for the funds awarded for the support of the project. The EPA regulations require applicant institutions to comply with the Department of Health and Human Services (DHHS) guidelines for human participants as well as additional requirements specified by the EPA. HEI is responsible for ensuring that these guidelines are followed by all Institutions and investigators receiving HEI funds.
The Institution must submit to HEI, for review, approval, and official acceptance, a written assurance of its compliance with guidelines established by the Department of Health and Human Services concerning protection of human participants. However, institutions that have submitted and have had accepted general assurance to DHHS under these guidelines will be considered as being in compliance with this requirement (as documented by form F-11). The DHHS’s regulation, 45 CFR 46, is available from the Office for Protection from Research Risks, National Institutes of Health, Bethesda, MD 20892, or from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20420, USA (or see http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html). Institutions outside the U.S. that have not obtained assurance of compliance to DHHS will need to provide assurance of compliance to the World Health Organization/Council for International Organizations of Medical Sciences (WHO/CIOMS), national agencies, or United Nations agencies.
If the application involves human participants, the application should include the following information on Form F-11:
• Identify the sources of the potential participants, derived materials, or data. Describe the characteristics of the participant population, such as their anticipated number, age, gender, ethnic background, and state of health. Identify the criteria for inclusion or exclusion. Explain the rationale for research involving fetuses, in vitro fertilization, pregnant women, children, institutionalized mentally disabled participants, prisoners, or other participants, especially those whose ability to give voluntary informed consent may be in question.
• Describe the recruitment and consent procedures to be followed, including the circumstances under which consent will be solicited and obtained, who will seek it, the nature of information to be provided to prospective participants, and the methods of documenting consent. Include the consent form to be used.
• Describe potential risks to the participants — physical, psychological, social, legal, or other — and assess their likelihood and seriousness. Describe alternative methods, if any, that were considered and why they will not be used.
• Describe the procedures for protecting against or minimizing potential risks and include an assessment of their likely effectiveness. Include a discussion of confidentiality safeguards, where relevant, and arrangements for providing medical treatment if needed.
• Describe and assess the potential benefits to be gained by the participants, as well as the benefits that may accrue to society in general as a result of the planned work.
• Discuss the risks in relation to the anticipated benefits to the participant and to society.
If HEI decides to fund a study involving human participants, the investigator will be asked to submit a detailed protocol before starting the study and to comply with HEI’s special QA/QC procedures (see HEI Project Negotiation, Project Management, and Investigator Commitment, and QA/QC Procedures). Approval of the study by the Institutional Review Board (IRB) at the investigator’s institution is required before starting a study with human participants. In addition, HEI will need to obtain approval from EPA before signing the contract, as described under HEI Project Negotiation, Project Management, and Investigator Commitment. Documentation submitted to HEI should include (1) the complete application to the IRB; (2) consent forms, if applicable; and (3) a signed letter from the IRB indicating that the study has been approved or exempted.
Laboratory Animals The applicant shall provide with the application written assurance that any use of laboratory animals will comply with the provisions of the Animal Welfare Act (7 U.S.C. S 2131 et. seq.) and the guidelines set forth in the Guide for the Care and Use of Laboratory Animals. These documents are available from the Office for the Protection from Research Risks, National Institutes of Health, Bethesda, MD 20892. When laboratory animals are to be used in the proposed studies, state the species, strains, ages, and numbers of the animals involved and the methods to be used to comply with the above-mentioned guidelines. If approval from the Institutional Animal Care and Use Committee has been obtained, the approval letter should be included with the application. Investigators are also encouraged to read the Animal Research: Reporting of In Vivo Experiments (ARRIVE) Guidelines (see http://www.nc3rs.org.uk/page.asp?id=1357). Although these guidelines pertain to reporting of research, HEI urges investigators to plan animal experiments being cognizant of the ARRIVE recommendations.
Recombinant DNA Applicants proposing work with recombinant DNA should adhere to the current NIH Guidelines for Research Involving Recombinant DNA Molecules. A copy of the Guidelines is available from the Office of Recombinant DNA Activities, National Institutes of Health, Bethesda, MD 20892.
Quality Assurance All applicants should provide a quality assurance plan that includes a list of standard operation procedures, qualifications of personnel, and other measures in place to assure the quality of the research and resulting data. In addition, HEI applies special QA procedures to all approved research projects that are anticipated to produce data of regulatory significance. This includes all human studies, as well as certain designated animal studies. Those studies will undergo an external audit, and the final report will include a QA Statement from the auditor(s). See Quality Assurance and Quality Control in HEI Project Negotiations, Management, and Investigator Commitments (separate document) and Appendix C for more details.
Sponsor Participation If “YES” has been marked under sponsor participation (i.e. any of the organizations funding HEI) on page F-8 of the application form (Other Support), please explain on a separate sheet the nature of sponsor participation. Identify and explain the role of any individual employed by EPA or industry sponsors of HEI who is involved with any aspect of the proposed study. Also, list any resources provided by sponsors, including animals, equipment, and facilities. Please note that employees of organizations funding HEI cannot receive funds from HEI for salary or any other costs.
Consultants Consultant arrangements and proposed collaborations with investigators at other institutions must be confirmed in writing. Attach appropriate letters from each individual, confirming his or her role in the project.
Statistician The assigned (bio)statistician needs to provide written confirmation that s/he (1) has reviewed and approved the study design and statistical approaches, and (2) will be actively involved in data analysis and interpretation.
Conflict of Interest (NEW) In addition to information on sources of Other Support (Form F-7), HEI requires investigators to disclose any personal conflicts of interest. Investigators should report financial relationships with entities in the exposure science or environmental health areas that could influence, or be perceived to influence, influencing, the proposed research. Please report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the past 36 months greater than $3,000. Disclose any personal fees (monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony) and non-financial support (for example reagents or equipment, travel costs, etc.). Report also any patents, whether planned, pending or issued, broadly relevant to the work. Report any other relationships or activities, including investment interests (stocks, bonds, and other financial instruments and investments, including partnerships).
Additional Materials (Rosenblith Award only) Applications to the Walter A. Rosenblith New Investigator Award should include a cover letter, two letters of reference, and the full application (one PDF file including the application itself and the following additional materials: a letter indicating institutional support, a mentoring plan with letters from each mentor, a list of all publications by the candidate, and three recent publications). Please refer to the RFA for details and use the designated set of application forms to assemble the materials in the order requested.
Personal Data (Form F-12 — OPTIONAL) HEI has a continuing commitment to monitoring the operation of its review and award process to detect, and deal appropriately with, real or imagined inequities with respect to age, ethnicity, race, or gender of the proposed principal investigator. To provide HEI with the information needed to fulfill this commitment, we request that each applicant complete the optional personal data form (Form F-12) and attach it as the last page of the signed original application. Upon receipt at the HEI office, this form will be separated from the application and used only for internal HEI monitoring procedures (please send this form as a separate PDF). If you do not wish to provide this information, or do not complete the form, it will in no way affect consideration of your application.
Please consult the Frequently Asked Questions before contacting HEI staff. Thank you!
Instructions to fill out the application (a pdf of the text on this page)
Negotiations and Investigator Commitments
HEI QA/QC Procedures
HEI Policy on Data Access
HEI's Conflict of Interest Policies
RFA 19-2 preliminary application form (revised March 19 2020)
RFA 19-2 Full Application Forms
RFA 20-1 preliminary application form
RFA 20-1 Full Application Forms ***These forms can be used for RFA 20-1A and RFA 20-1B***
Form F-9 Biosketch
Form to submit a QA Plan